Activated Charcoal Use in Chronic Kidney Disease Patients

Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06906874

Enrollment

Registered

2025-04-02

Start date

2025-08-31

Completion date

2025-11-30

Last updated

2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Brief summary

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Interventions

DRUGActivated Charcoal

oral activated charcoal capsules

DRUGPhosphate Binders

calcium-based or non-calcium based (sevelamer) binders

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult aged ≥18 years with ESRD. 2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months. 3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).

Exclusion criteria

1. Severely malnourished (as diagnosed by the department's dietitian). 2. Treated with overnight dialysis. 3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.

Design outcomes

Primary

Measure	Time frame	Description
Serum phosphorus levels	8 weeks	Difference between two groups of serum phosphorous level in mg/dL at the end of the study.

Secondary

Measure	Time frame	Description
The percentage of patients who achieved decreasing at least 3 points in The Worst Itching Intensity Numerical Rating Scale (WI NRS)	8 weeks	The (WI-NRS) is a validated 11-point scale, with scores ranging from 0 to 10 and with higher scores indicating greater itch intensity.

Countries

Egypt

Contacts

Primary ContactBasma M. Sayed Ahmed, M.Sc.

basma_mohamed@mans.edu.eg+201207753307

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026